Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1

Binbin Cheng , Yaping Wang , Yimeng Hong , Yingxing Zhou , Xiaopeng Peng , Jianjun Chen , Chunlai Zeng

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101125

PDF (4169KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101125 DOI: 10.1016/j.ajps.2026.101125
Review Article
research-article
Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1
Author information +
History +
PDF (4169KB)

Abstract

Molecular glues (MGs), a class of small-molecule degraders, exhibit drug-like properties that generally conform to Lipinski’s rule of five, while uniquely mediating the stabilization or induction of protein-protein interactions. By altering the surface properties of either target proteins or E3 ligases, MGs promote the formation of a ternary complex comprising the MG, an E3 ligase, and a target protein. This interaction facilitates the polyubiquitination and subsequent degradation of the target protein via the ubiquitin-proteasome system. Owing to its distinctive mechanism of action and broad therapeutic potential, MG is offering novel approaches to disease treatment. This review summarizes recent advances in MGs targeting NEK7, WEE1, CDK2, GSPT1 and VAV1, emphasizing the rational design, benefits, and potential limitations, highlighting rational design principles, advantages, and current limitations including challenges in achieving selectivity and rational design that provide critical insights for enhancing MG efficacy. These developments are crucial for advancing the application and optimization of molecular glues targeting NEK7, WEE1, CDK2, GSPT1 and VAV1.

Keywords

Small-molecule degrader / NEK7 / WEE1 / CDK2 / GSPT1 / VAV1

Cite this article

Download citation ▾
Binbin Cheng, Yaping Wang, Yimeng Hong, Yingxing Zhou, Xiaopeng Peng, Jianjun Chen, Chunlai Zeng. Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101125 DOI:10.1016/j.ajps.2026.101125

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 2022; 21(3): 181-200.

[2]

Hsia O, Hinterndorfer M, Cowan AD, Iso K, Ishida T, Sundaramoorthy R, et al. Targeted protein degradation via intramolecular bivalent glues. Nature 2024; 627(8002): 204-11.

[3]

Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 2022; 7(1): 113.

[4]

Dong G, Ding Y, He S, Sheng C. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J Med Chem 2021; 64(15): 10606-20.

[5]

Song J, Hu M, Zhou J, Xie S, Li T, Li Y, et al. Targeted protein degradation in drug development: recent advances and future challenges. Eur J Med Chem 2023; 261: 115839.

[6]

Kim J, Byun I, Kim DY, Joh H, Kim HJ, Lee MJ, et al. Targeted protein degradation directly engaging lysosomes or proteasomes. Chem Soc Rev 2024; 53(7): 3253-72.

[7]

Samarasinghe KTG, Crews CM. Targeted protein degradation: a promise for undruggable proteins. Cell Chem Biol 2021; 28(7): 934-51.

[8]

Kong NR, Jones LH. Clinical translation of targeted protein degraders. Clin Pharmacol Ther 2023; 114(3): 558-68.

[9]

Stockley ML, Ferdinand A, Benedetti G, Blencowe P, Boyd SM, Calder M, et al. Discovery, characterization, and structure-based optimization of small-molecule in vitro and in vivo probes for human DNA polymerase theta. J Med Chem 2022; 65(20): 13879-91.

[10]

Mayor-Ruiz C, Bauer S, Brand M, Kozicka Z, Siklos M, Imrichova H, et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat Chem Biol 2020; 16(11): 1199-207.

[11]

Lemaitre T, Cornu M, Schwalen F, Since M, Kieffer C, Voisin-Chiret AS, et al. Molecular glue degraders: exciting opportunities for novel drug discovery. Expert Opin Drug Discov 2024; 19(5): 433-49.

[12]

Oleinikovas V, Gainza P, Ryckmans T, Fasching B, Thoma NH. From thalidomide to rational molecular glue design for targeted protein degradation. Annu Rev Pharmacol Toxicol 2024; 64: 291-312.

[13]

Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C. Chasing molecular glue degraders: screening approaches. Chem Soc Rev 2022; 51(13): 5498-517.

[14]

Cao S. Lessons from natural molecular glue degraders. Biochem Soc Trans 2024; 52(3): 1191-7.

[15]

Cheng B, Li H, Peng X, Chen J, Shao C, Kong Z, et al. Recent advances in developing targeted protein degraders. Eur J Med Chem 2025; 284: 117212.

[16]

Kuchta R, Heim C, Herrmann A, Maiwald S, Ng YLD, Sosic I, et al. Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design. RSC Chem Biol 2023; 4(3): 229-34.

[17]

Watson ER, Novick S, Matyskiela ME, Chamberlain PP, de la Peña A A, Zhu J, et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 2022; 378(6619): 549-53.

[18]

Asatsuma-Okumura T, Ito T, Handa H. Molecular mechanisms of cereblon-based drugs. Pharmacol Ther 2019; 202: 132-9.

[19]

Ito T, Yamaguchi Y, Handa H. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology. Cell Chem Biol 2021; 28(7): 987-99.

[20]

Zhou Y, Garrigues SL, Villemure E, Ishisoko N, Nguyen HQ, Hamidi NK, et al. Heteroaryl glutarimides and dihydrouracils as cereblon ligand scaffolds for molecular glue degrader discovery. ACS Med Chem Lett 2024; 15(12): 2158-63.

[21]

Merino-Cacho L, Barroso-Gomila O, Pozo-Rodriguez M, Muratore V, Guinea-Perez C, Serrano A, et al. Cullin-RING ligase BioE3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous cereblon ubiquitome. Cell Commun Signal 2025; 23: 101.

[22]

Bailey HJ, Eisert J, Kazi R, Gerhartz J, Pienkowska DE, Dressel I, et al. An engineered cereblon optimized for high-throughput screening and molecular glue discovery. Cell Chem Biol 2025; 32(3): 363-76.

[23]

Ito T. Protein degraders - from thalidomide to new PROTACs. J Biochem 2024; 175(6): 507-19.

[24]

Liu Y, Bai J, Li D, Cang Y. Routes to molecular glue degrader discovery. Trends Biochem Sci 2025; 50(2): 134-42.

[25]

Hemant Kumar S, Venkatachalapathy M, Sistla R, Poongavanam V. Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation. Drug Discov Today 2024; 29(3): 104205.

[26]

Meyers M, Cismoski S, Panidapu A, Chie-Leon B, Nomura DK. Targeted protein degradation through recruitment of the CUL4 complex adaptor protein DDB1. ACS Chem Biol 2024; 19(1): 58-68.

[27]

Sasso JM, Tenchov R, Wang D, Johnson LS, Wang X, Zhou QA, et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry 2023; 62(3): 601-23.

[28]

Yan J, Zheng Z. Discovery of highly potent CRBN ligands and insight into their binding mode through molecular docking and molecular dynamics simulations. ChemMedChem 2023; 18(5): e202200573.

[29]

Krasavin M, Adamchik M, Bubyrev A, Heim C, Maiwald S, Zhukovsky D, et al. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor cereblon (CRBN): investigation of their binding mode and antiproliferative effects against myeloma cell lines. Eur J Med Chem 2023; 246: 114990.

[30]

Fang Y, He Q, Cao J. Targeted protein degradation and regulation with molecular glue: past and recent discoveries. Curr Med Chem 2022; 29(15): 2490-503.

[31]

Chen S, Cui J, Chen H, Yu B, Long S. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques. Eur J Med Chem 2023; 262: 115911.

[32]

Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, et al. Degraders in epigenetic therapy: PROTACs and beyond. Theranostics 2024; 14(4): 1464-99.

[33]

Sharif H, Wang L, Wang WL, Magupalli VG, Andreeva L, Qiao Q, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 2019; 570(7761): 338-43.

[34]

Zheng S, Que X, Wang S, Zhou Q, Xing X, Chen L, et al. ZDHHC5-mediated NLRP3 palmitoylation promotes NLRP3-NEK7 interaction and inflammasome activation. Mol Cell 2023; 83(24): 4570-85.

[35]

Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-kappaB signaling. Cell Death Dis 2019; 10(12): 906.

[36]

Wang J, Chen S, Liu M, Zhang M, Jia X. NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases. Inflammopharmacology 2022; 30(4): 1179-87.

[37]

Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol 2016; 17(3): 250-8.

[38]

Li YK, Zhu XR, Zhan Y, Yuan WZ, Jin WL. NEK7 promotes gastric cancer progression as a cell proliferation regulator. Cancer Cell Int 2021; 21(1): 438.

[39]

Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature 2023; 613(7944): 595-600.

[40]

Zhao N, Li CC, Di B, Xu LL. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: mechanisms, role in diseases and related inhibitors. J Autoimmun 2020; 113: 102515.

[41]

Wen L, Quan Z, Guan C, Zheng J, Li Y, Zeng S, et al. Targeted inhibition of NEK7 preventing sepsis-induced cardiomyopathy by inhibiting NLRP3 inflammasome. Int Immunopharmacol 2025; 151: 114245.

[42]

Jin X, Yang Y, Liu D, Zhou X, Huang Y. Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation. Cell Commun Signal 2024; 22(1): 565.

[43]

Liu H, Gu C, Liu M, Liu G, Wang Y. NEK7 mediated assembly and activation of NLRP3 inflammasome downstream of potassium efflux in ventilator-induced lung injury. Biochem Pharmacol 2020; 177: 113998.

[44]

Gupta S, Cassel SL, Sutterwala FS, Dagvadorj J. Regulation of the NLRP3 inflammasome by autophagy and mitophagy. Immunol Rev 2025; 329(1): 8-19.

[45]

Wang L, Zhu K, Tian Z, Wang H, Jia Y, Feng C, et al. Discovery of novel biaryl urea derivatives against IL-1beta release with low toxicity based on NEK7 inhibitor. Eur J Med Chem 2025; 283: 117125.

[46]

Coll RC, Schroder K. Inflammasome components as new therapeutic targets in inflammatory disease. Nat Rev Immunol 2025; 25(1): 22-41.

[47]

Vande Walle L, Lamkanfi M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov 2024; 23(1): 43-66.

[48]

Panchal NK, Evan Prince S. The NEK family of serine/threonine kinases as a biomarker for cancer. Clin Exp Med 2023; 23(1): 17-30.

[49]

Jeltema D, Wang J, Cai J, Kelley N, Yang Z, He Y. A single amino acid residue defines the difference in NLRP3 inflammasome activation between NEK7 and NEK6. J Immunol 2022; 208(9): 2029-36.

[50]

Moraes EC, Meirelles GV, Honorato RV, de Souza Tde A, de Souza EE, Murakami MT, et al. Kinase inhibitor profile for human nek1, nek6, and nek7 and analysis of the structural basis for inhibitor specificity. Molecules 2015; 20(1): 1176-91.

[51]

Chen L, Huang L, Wen W, Zeng P, Wu Y, Han Q, et al. Selective and potent molecular glue degraders for NIMA-related kinase 7. Angew Chem Int Ed Engl 2025; 64(12): e202500169.

[52]

Sylvain A, Stoehr N, Ma F, Cernijenko A, Schroder M, Khoshouei M, et al. A cereblon-based glue degrader of NEK7 regulates NLRP3 inflammasome in a context-dependent manner. Cell Chem Biol 2025; 32(6): 955-68.

[53]

Elbaek CR, Petrosius V, Sorensen CS. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res 2020; 819-820: 111694.

[54]

Elbaek CR, Petrosius V, Benada J, Erichsen L, Damgaard RB, Sorensen CS. WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. Cell Rep 2022; 38(3): 110261.

[55]

Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med 2020; 22: e2.

[56]

Du X, Li J, Luo X, Li R, Li F, Zhang Y, et al. Structure-activity relationships of Wee1 inhibitors: a review. Eur J Med Chem 2020; 203: 112524.

[57]

Kong A, Mehanna H. WEE1 inhibitor: clinical development. Curr Oncol Rep 2021; 23(9): 107.

[58]

Alli VJ, Yadav P, Suresh V, Jadav SS. Synthetic and medicinal chemistry approaches toward WEE1 kinase inhibitors and its degraders. ACS Omega 2023; 8(23): 20196-233.

[59]

Yan J, Zhuang L, Wang Y, Jiang Y, Tu Z, Dong C, et al. Inhibitors of cell cycle checkpoint target Wee1 kinase-a patent review (2003-2022). Expert Opin Ther Pat 2022; 32(11): 1217-44.

[60]

Sidaway P. WEE1 kinase inhibitor shows promise. Nat Rev Clin Oncol 2019; 16(10): 593.

[61]

Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today 2020; 25(2): 406-13.

[62]

Fagundes R, Teixeira LK. Cyclin E/CDK2: DNA replication, replication stress and genomic instability. Front Cell Dev Biol 2021; 9: 774845.

[63]

Zhang J, Gan Y, Li H, Yin J, He X, Lin L, et al. Inhibition of the CDK2 and cyclin A complex leads to autophagic degradation of CDK2 in cancer cells. Nat Commun 2022; 13(1): 2835.

[64]

Liu Q, Gao J, Zhao C, Guo Y, Wang S, Shen F, et al. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. DNA Repair (Amst) 2020; 85: 102702.

[65]

Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem 2019; 62(9): 4233-51.

[66]

Said MA, Abdelrahman MA, Abourehab MAS, Fares M, Eldehna WM. A patent review of anticancer CDK2 inhibitors (2017-present). Expert Opin Ther Pat 2022; 32(9): 885-98.

[67]

Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur J Med Chem 2022; 230: 114109.

[68]

Yu D, Zeng L, Wang Y, Cheng B, Li D. Protein arginine methyltransferase 7 modulators in disease therapy: current progress and emerged opportunity. Bioorg Chem 2025; 154: 108094.

[69]

Li Z, Pinch BJ, Olson CM, Donovan KA, Nowak RP, Mills CE, et al. Development and characterization of a Wee1 kinase degrader. Cell Chem Biol 2020; 27(1): 57-65.

[70]

Guler S, DiPoto MC, Crespo A, Caldwell R, Doerfel B, Grossmann N, et al. Selective Wee1 inhibitors led to antitumor activity in vitro and correlated with myelosuppression. ACS Med Chem Lett 2023; 14(5): 566-76.

[71]

Razumkov H, Jiang Z, Baek K, You I, Geng Q, Donovan KA, et al. Discovery of CRBN-dependent WEE1 molecular glue degraders from a multicomponent combinatorial library. J Am Chem Soc 2024; 146: 31433-43.

[72]

Razumkov H, Jiang Z, Baek K, You I, Geng Q, Donovan KA, et al. Discovery of CRBN-dependent WEE1 molecular glue degraders from a multicomponent combinatorial library. J Am Chem Soc 2024; 146(46): 31433-43.

[73]

Brown VE, Moore SL, Chen M, House N, Ramsden P, Wu HJ, et al. CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination. NAR Cancer 2023; 5(2): zcad039.

[74]

Zeng Y, Ren X, Jin P, Fan Z, Liu M, Zhang Y, et al. Inhibitors and PROTACs of CDK2: challenges and opportunities. Expert Opin Drug Discov 2024; 19(9): 1125-48.

[75]

Wang L, Shao X, Zhong T, Wu Y, Xu A, Sun X, et al. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol 2021; 17(5): 567-75.

[76]

Zhou F, Chen L, Cao C, Yu J, Luo X, Zhou P, et al. Development of selective mono or dual PROTAC degrader probe of CDK isoforms. Eur J Med Chem 2020; 187: 111952.

[77]

Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, et al. Development of CDK2 and CDK5 dual degrader TMX-2172. Angew Chem Int Ed Engl 2020; 59(32): 13865-70.

[78]

Sasayama T, Hamada T, Tanaka K, Nagashima H, Yamanishi S, Ueyama T. Potential of GSPT1 as a novel target for glioblastoma therapy. Cell Death Dis 2024; 15(7): 572.

[79]

Sellar RS, Sperling AS, Slabicki M, Gasser JA, McConkey ME, Donovan KA, et al. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. J Clin Invest 2022; 132(8): e153514.

[80]

Zhang D, Lin P, Lin J. Molecular glues targeting GSPT1 in cancers: a potent therapy. Bioorg Chem 2024; 143: 107000.

[81]

Jackson RJ, Hellen CU, Pestova TV. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 2010; 11(2): 113-27.

[82]

Hinnebusch AG. The scanning mechanism of eukaryotic translation initiation. Annu Rev Biochem 2014; 83: 779-812.

[83]

Le Roy F, Salehzada T, Bisbal C, Dougherty JP, Peltz SW. A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol 2005; 12(6): 505-12.

[84]

Kozlov G, Gehring K. Molecular basis of eRF3 recognition by the MLLE domain of poly(A)-binding protein. PLoS One 2010; 5(4): e10169.

[85]

Chang X, Qu F, Li C, Zhang J, Zhang Y, Xie Y, et al. Development and therapeutic potential of GSPT1 molecular glue degraders: a medicinal chemistry perspective. Med Res Rev 2024; 44(4): 1727-67.

[86]

Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev 2023; 57: 100994.

[87]

Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 2016; 535(7611): 252-7.

[88]

Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 2021; 137(5): 661-77.

[89]

Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, et al. CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia. J Med Chem 2021; 64(4): 1835-43.

[90]

Huber AD, Li Y, Lin W, Galbraith AN, Mishra A, Porter SN, et al. SJPYT-195: a designed nuclear receptor degrader that functions as a molecular glue degrader of GSPT1. ACS Med Chem Lett 2022; 13(8): 1311-20.

[91]

Shen H, Xu H, Jin W, Wu T, Hu J, Zhang C, et al. Discovery of a potent and selective GSPT1 molecular glue degrader for the treatment of castration-resistant prostate cancer. J Med Chem 2025; 68(3): 1553-71.

[92]

Chang Y, Keramatnia F, Ghate PS, Nishiguchi G, Gao Q, Iacobucci I, et al. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood 2023; 142(7): 629-42.

[93]

Nishiguchi G, Keramatnia F, Min J, Chang Y, Jonchere B, Das S, et al. Identification of potent, selective, and orally bioavailable small-molecule GSPT1/2 degraders from a focused library of cereblon modulators. J Med Chem 2021; 64(11): 7296-311.

[94]

Powell CE, Du G, Che J, He Z, Donovan KA, Yue H, et al. Selective degradation of GSPT1 by cereblon modulators identified via a focused combinatorial library. ACS Chem Biol 2020; 15(10): 2722-30.

[95]

Zhang S, Nie S, Ma G, Shen M, Kong L, Zuo Z, et al. Identification of novel GSPT1 degraders by virtual screening and bioassay. Eur J Med Chem 2024; 273: 116524.

[96]

Zhang Y, Liu W, Tong C, Wang X, Chang X, Qu F, et al. Design and discovery of preclinical candidate LYG-409 as a highly potent and selective GSPT1 molecular glue degraders. J Med Chem 2025; 68(4): 2608-38.

[97]

Wei Y, Xu X, Jiang M, Wang Y, Zhou Y, Wang Z, et al. Discovery of new lenalidomide derivatives as potent and selective GSPT1 degraders. Eur J Med Chem 2023; 258: 115580.

[98]

Liu Y, Sun X, Liu Q, Han C, Rao Y. A dual-target and dual-mechanism design strategy by combining inhibition and degradation together. J Am Chem Soc 2025; 147(7): 3110-3118.

[99]

Yang Z, Sun Y, Ni Z, Yang C, Tong Y, Liu Y, et al. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Res 2021; 31(12): 1315-18.

[100]

Xu Y, Yang H, Li Y, Qi Y, Zhao F, Hong Y, et al. Discovery of highly potent dual GSPT1/BRD4 degraders with anti-AML activity. Eur J Med Chem 2025; 288: 117381.

[101]

Shalom B, Salaymeh Y, Risling M, Katzav S. Unraveling the oncogenic potential of VAV1 in human cancer: lessons from mouse models. Cells 2023; 12(9): 1276.

[102]

Neurath MF, Berg LJ. VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases. Trends Immunol 2024; 45(7): 580-96.

[103]

Tybulewicz VL, Ardouin L, Prisco A, Reynolds LF. Vav1: a key signal transducer downstream of the TCR. Immunol Rev 2003; 192: 42-52.

[104]

Pawlik A, Malinowski D, Paradowska-Gorycka A, Safranow K, Dziedziejko V. VAV1 gene polymorphisms in patients with rheumatoid arthritis. Int J Environ Res Public Health 2020; 17(9): 3214.

[105]

Qiu J, Guo J, Liu L, Liu X, Sun X, Chen H. Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation. Neural Regen Res 2023; 18(11): 2436-42.

[106]

Wang Q, Gong L, Mao S, Yao C, Liu M, Wang Y, et al. Klf2-Vav1-Rac1 axis promotes axon regeneration after peripheral nerve injury. Exp Neurol 2021; 343: 113788.

PDF (4169KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉